Can a seizure drug tame autism irritability? new trial aims to find out

NCT ID NCT07635862

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests whether ganaxolone, a drug already approved for certain seizures, can reduce irritability in autistic children aged 5 to 17. About 66 participants will receive either the drug or a placebo for 12 weeks. The main goal is to see if it improves emotional regulation and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
ganaxolone (Ztalmy)
What this could lead to
If it works, this could offer a new option to reduce irritability and repetitive behaviors in autistic children, improving daily life.
What could go wrong
This is an early phase 2 trial with only 66 participants, so results may not apply widely. The drug may cause side effects or show no benefit over placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTISM IN CHILDREN are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Stanford University

    Stanford, California, 94305, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.